Would you continue venetoclax indefinitely beyond standard fixed-duration therapy with ven/obinutuzumab for a patient with high-risk TP53-mutated/del17p CLL refractory to initial acalabrutinib with ALC doubling time < 6 months without BTK resistance mutations?
Is there rationale to re-introduce a BTK inhibitor?
Community PollStarted
Would you continue venetoclax indefinitely beyond standard fixed-duration therapy with ven/obinutuzumab for a patient with high-risk del17p CLL refractory to initial acalabrutinib with ALC doubling time < 6 months without BTK resistance mutations?
7 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UPMC Hillman Cancer Center
Answered on
This patient has covalent BTKi (cBTKi) resistance without a resistance mutation and was transitioned to venetoclax + obinutuzumab. Overall, this patient is not going to do well and in addition to initiating therapy, the provider should refer this patient to a CLL expert provider for co-management. T...
Join for free or sign in to see the full answer